Targets › MDM2
6 programs from 6 companies in 20 trials: 10 Phase 1, 9 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. (UniProt, Q00987)
Open in Phaseline: the race on MDM2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kartos Therapeutics | Navtemadlin (KRT-232) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 3 | Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma … | Dec 2026 |
| Ascentage Pharma Group | APG-115 MDM2 inhibitor | MDM2 | Phase 2 | T-Prolymphocytic Leukemia; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Liposarcoma; Neuroblastoma … | Jan 2027 |
| Centre Leon Berard | Siremadlin (HDM201) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 2 | Malignant Solid Tumor; Advanced Soft-tissue Sarcoma | Feb 2027 |
| University of Washington | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX | ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma | Apr 2027 |
| Boehringer Ingelheim | Brigimadlin MDM2 inhibitor | MDM2 | Phase 2 | Solid Tumours | Dec 2030 |
| AeRang Kim | Alrizomadlin (APG-115) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 1 | Malignant Peripheral Nerve Sheath Tumor (MPNST) | Oct 2027 |
Acute Myeloid Leukemia (2) Anatomic Stage IV Breast Cancer AJCC v8 (2) Malignant Solid Tumor (1) Advanced Soft-tissue Sarcoma (1) T-Prolymphocytic Leukemia (1) Unresectable or Metastatic Melanoma or Advanced Solid Tumors (1) Liposarcoma (1) Neuroblastoma (1) Malignant Salivary Gland Cancer (1) Myelofibrosis (1) Polycythemia Vera (1) Endometrial Cancer (1)
small molecule (4), mixed (2)
Centre Leon Berard (1) Ascentage Pharma Group (1) Kartos Therapeutics (1) University of Washington (1) AeRang Kim (1) Boehringer Ingelheim (1)
TP53 (3) ENG (1) YBX1 (1) SOX2 (1) CDH3 (1) CD105 (1) YB1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.